<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869371</url>
  </required_header>
  <id_info>
    <org_study_id>IUNU-PC-106</org_study_id>
    <nct_id>NCT04869371</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer</brief_title>
  <official_title>A Randomized, Controlled, Single Center Clinical Trial to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hongqian Guo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled, single center clinical trial aims to evaluate the efficacy and&#xD;
      safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer&#xD;
      with a six-month treatment cycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Minimal Residual Disease</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects that have residual tumors with maximum diameter of 3 mm or less after radical prostatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging Response Rate</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects whose primary tumor is in complete remission on imaging or residual tumor's maximum diameter is less than 0.5cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual cancer burden (RCB)</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Evaluated by Residual Cancer Burden Calculator based on Primary Tumor Bed and Lymph Nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stage Degradation</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Clinical or pathological stage degradation after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Positive Surgical Margins</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects with positive surgical margins after radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response to treatment</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Group 0-3, The University of Texas M.D. Anderson Cancer Center evaluation criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without PSA progression</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects whose PSA has never gone below 1 ng/ml or who receive any radiotherapy or systemic treatment after radical prostatectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Serum Remission</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The proportion of subjects whose PSA is less than or equal to 0.2 ng/ml after 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time (min)</measure>
    <time_frame>12 month</time_frame>
    <description>The operative time(min) of radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss (ml)</measure>
    <time_frame>12 month</time_frame>
    <description>Estimated blood loss (ml) during the process of radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay (day)</measure>
    <time_frame>12 month</time_frame>
    <description>The hospitalization time, recorded in day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drainage duration (day)</measure>
    <time_frame>12 month</time_frame>
    <description>Length of drainage duration, recorded in day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications (%)</measure>
    <time_frame>12 month</time_frame>
    <description>The proportion of subjects who suffer from major complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time of urinary continence (day)</measure>
    <time_frame>12 month</time_frame>
    <description>The recovery time of urinary continence (day) after radical prostatectomy, defined as 0 pad/day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel</condition>
  <arm_group>
    <arm_group_label>Androgen Deprivation Therapy with Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel injection</intervention_name>
    <description>75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy</description>
    <arm_group_label>Androgen Deprivation Therapy with Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate for Injectable Suspension</intervention_name>
    <description>15mg every 12 weeks</description>
    <arm_group_label>ADT alone</arm_group_label>
    <arm_group_label>Androgen Deprivation Therapy with Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone Acetate Tablets</intervention_name>
    <description>5 mg oral low dose prednisone, once daily</description>
    <arm_group_label>Androgen Deprivation Therapy with Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 and ≤75 years of age.&#xD;
&#xD;
          -  All patients must have a histologically or cytologically diagnosis of prostate cancer&#xD;
             and must be eligible for radical prostatectomy.&#xD;
&#xD;
          -  All patients must undergo thorough tumor staging and meet one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥&#xD;
                  T3,&#xD;
&#xD;
               2. Gleason score of primary tumor ≥ 8, 3.prostate specific antigen (PSA) ≥20 ng/ml.&#xD;
&#xD;
               3. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1.&#xD;
&#xD;
               4. Patients must have adequate hematologic function, within 28 days prior to&#xD;
                  registration as evidenced by: white blood cell (WBC) ≥ 4.0 × 109 /L, platelets≥&#xD;
                  100 × 109 / L, hemoglobin ≥ 9 g / dL, and international normalized ratio (INR) &lt;&#xD;
                  1.5.&#xD;
&#xD;
               5. Patients must have adequate hepatic function, within 28 days prior to&#xD;
                  registration, as evidenced by: total bilirubin (TBIL)≤1.5 x upper limit of normal&#xD;
                  (ULN),and SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN.&#xD;
&#xD;
               6. Patients must have adequate renal function, within 28 days prior toregistration,&#xD;
                  as evidenced by serum creatinine ≤2×ULN&#xD;
&#xD;
          -  Patients must participate voluntarily and sign an informed consent form(ICF),&#xD;
             indicating that they understand the purpose and required procedures of the study, and&#xD;
             are willing to participate in. Patients must be willing to obey the prohibitions and&#xD;
             restrictions specified in the research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are&#xD;
             not eligible.&#xD;
&#xD;
          -  Patients with low-risk and medium-risk, localized prostate cancer (the following&#xD;
             conditions are met at the same time) are not eligible: multiparameter MRI or PSMA PET&#xD;
             / CT shows clinical staging of primary tumor &lt; T3, Gleason score of primary tumor &lt; 8,&#xD;
             and prostate specific antigen (PSA) &lt;20 ng/ml.&#xD;
&#xD;
          -  Patients with clinical or radiological evidence of extra-regional lymph node&#xD;
             metastases or bone metastases or visceral metastases are not eligible.&#xD;
&#xD;
          -  Patients who have previously received androgen deprivation therapy (medical or&#xD;
             surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or&#xD;
             prostate cancer chemotherapy are not eligible.&#xD;
&#xD;
          -  Patients with severe or uncontrolled concurrent infections are not eligible.&#xD;
&#xD;
          -  Patients must not have New York Heart Association Class III or IV congestive heart&#xD;
             failure at the time of screening. Patients must not have any thromboembolic event,&#xD;
             unstable angina pectoris, myocardial infarction within 6 months prior to registration.&#xD;
&#xD;
          -  Patients must not have uncontrolled severe hypertension, persistent uncontrolled&#xD;
             diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.&#xD;
&#xD;
          -  Patients must not have had other malignancies other than prostate cancer in the past 5&#xD;
             years, but cured basal cell or squamous cell skin cancers can be enrolled.&#xD;
&#xD;
          -  Patients with mental illness, mental disability or inability to give informed consent&#xD;
             are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqian Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, affiliated to medical school of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlong Zhuang, PhD</last_name>
    <phone>+86 15950451917</phone>
    <email>zhuangjl-2008@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlong Zhuang, PhD</last_name>
      <phone>8615950451917</phone>
      <email>zhuangjl-2008@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

